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RESEARCH ARTICLE Open Access
5-Fluorouracil upregulates cell surface B7-
H1 (PD-L1) expression in gastrointestinal
cancers
Lauren Van Der Kraak1†, Gaurav Goel2,3†, Krishnaveni Ramanan4, Christof Kaltenmeier4, Lin Zhang5,
Daniel P. Normolle6, Gordon J. Freeman7, Daolin Tang4, Katie S. Nason1, Jon M. Davison8, James D. Luketich1,
Rajeev Dhupar1† and Michael T. Lotze4,9,10*†
Abstract
Background: Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients.
B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is
overexpressed in several human cancers. Interaction of B7-H1 with programmed death 1 (PD-1) prevents T-cell
activation and proliferation, sequestering the T-cell receptor from the cell membrane, inducing T-cell apoptosis,
thereby leading to cancer immunoresistance. B7-H1 upregulation contributes to chemoresistance in several types of
cancer, but little is known with respect to changes associated with 5-fluorouracil (5-FU) or gastrointestinal cancers.
Methods: HCT 116 p53+/+, HCT 116 p53−/− colorectal cancer (CRC) and OE33 esophageal adenocarcinoma (EAC)
cells were treated with increasing doses of 5-FU (0.5 uM, 5 uM, 50 uM, 500 uM) or interferon gamma (IFN-γ, 10 ng/
mL) in culture for 24 h and B7-H1 expression was quantified using flow cytometry and western blot analysis. We
also evaluated B7-H1 expression, by immunohistochemistry, in tissue collected prior to and following neoadjuvant
therapy in 10 EAC patients.
Results: B7-H1 expression in human HCT 116 p53+/+ and HCT 116 p53−/− CRC cells lines, while low at baseline, can
be induced by treatment with 5-FU. OE33 baseline B7-H1 expression exceeded CRC cell maximal expression and
could be further increased in a dose dependent manner following 5-FU treatment in the absence of immune cells.
We further demonstrate tumor B7-H1 expression in esophageal adenocarcinoma patient-derived pre-treatment
biopsies. While B7-H1 expression was not enhanced in post-treatment esophagectomy specimens, this may be due
to the limits of immunohistochemical quantification.
Conclusions: B7-H1/PD-L1 expression can be increased following treatment with 5-FU in gastrointestinal cancer
cell lines, suggesting alternative mechanisms to classic immune-mediated upregulation. This suggests that
combining 5-FU treatment with PD-1/B7-H1 blockade may improve treatment in patients with gastrointestinal
adenocarcinoma.
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* Correspondence: lotzemt@upmc.edu
Lauren Van Der Kraak and Gaurav Goel qualify as co-first authors.
Rajeev Dhupar and Michael T. Lotze qualify as co-last authors.
†Equal contributors
4Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA
9Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Van Der Kraak et al. Journal for ImmunoTherapy of Cancer  (2016) 4:65 
DOI 10.1186/s40425-016-0163-8
Background
5-Fluorouracil (5-FU), a uracil mimetic, is a chemothera-
peutic drug commonly used to treat patients with ad-
vanced anal, colorectal (CRC), stomach, breast,
esophageal and head/neck cancers [1–4]. It induces cell
death through the inhibition of thymidylate synthase
and through its misincorporation into newly synthesized
DNA and RNA [4]. 5-FU exerts the most robust re-
sponse in combination with irinotecan and oxaliplatin
in CRC, with response rates of 40-50 % [4]. Both in-
nate and acquired chemoresistance continue to be im-
portant obstacles in the effective treatment of patients
using 5-FU.
In recent years, there has been increasing evidence to
support a role for the immune system in effective 5-FU
treatment and the development of chemoresistance [5].
These include induction of Heat Shock Protein 70 on
tumor cells following treatment leading to enhanced
tumor uptake by dendritic cells. Subsequent IL-12 secre-
tion and enhanced antigen presentation and induced ex-
pression of Intercellular Adhesion Molecule 1 and Fas
ligand can result in tumor cell elimination by T-cells [6,
7]. Reduction in the frequency of circulating and tumor-
infiltrating myeloid-derived suppressor cells (MDSCs)
via induction of 5-FU-induced apoptotic cell death may
itself promote changes in the expression of B7-H1 [5–8].
B7-homolog 1 (B7-H1), also known as programmed
death ligand-1 (PD-L1), is an immunoregulatory protein
that belongs to the B7 family of T-cell co-regulatory
molecules [9]. It is one of two ligands for the PD-1 re-
ceptor (CD279), a costimulatory molecule expressed on
the surface of T-cells [10]. Interaction of B7-H1 with
PD-1 prevents T-cell activation and proliferation, thus
inducing T-cell apoptosis, leading to cancer immunore-
sistance [11]. B7-H1 is overexpressed in solid cancers,
including breast, colon, esophageal, gastric, lung, ovarian
and pancreatic cancers, and is often categorized as a
poor prognostic factor, although occasionally it has been
shown as a favorable factor [12]. Interestingly B7-H1 ex-
pression can be induced in cells and tissue following
treatment with chemotherapeutic agents. For example,
McDaniel et al. demonstrated increased B7-H1 in
urothelial carcinoma tumor cores following treatment
with cisplatin/carboplatin [13]. Paclitaxel induces B7-H1
expression in the human colon cancer cell-line SW480
and the hepatocellular carcinoma cell-line HepG2 via
the mitogen-activated protein kinase pathway [14]. How-
ever, little is known about the effects of 5-FU treatment
on B7-H1 expression in digestive cancers, although 5-
FU treatment upregulates B7-H1 in MDA-MB 408 and
435 breast cancer cell lines, but not MCF-7 cells [15].
Herein, we investigate B7-H1 expression following
treatment with 5-FU in several gastrointestinal cancer
cell lines. Mutations in the p53 tumor suppressor have
been associated with both poor responsiveness to 5-FU
and microRNA-34 upregulation of B7-H1 [16–19].
Therefore, we investigated B7-H1 expression following
5-FU treatment in both HCT 116 p53+/+ and HCT 116
p53−/− CRC cells. We also investigated B7-H1 expression
in OE33 Barrett’s-derived esophageal adenocarcinoma
cells, since B7-H1 expression has been found in patients
with advanced Barrett’s carcinoma, but the influence of
chemotherapy on B7-H1 is not known [20].
Methods
Cell culture
Human colorectal cancer cell lines (HCT 116 p53 +/+,
HCT 116 p53 −/−, HT29 and SW480) were obtained
from Dr. Edward Chu and Dr. Lin Zhang (University of
Pittsburgh Medical Center) and confirmed to be myco-
plasma negative using the MycoAlertTM mycoplasma de-
tection kit (Lonza Group Ltd, Allendale, NJ). OE33,
esophageal adenocarcinoma cells from a patient with
Barrett’s esophagus were purchased from Sigma Aldrich
(St. Louis, MO). All cells were grown in RPMI 1640 plus
2.05 mM glutamine media that had been supplemented
with 1× penicillin-streptomycin and 10 % fetal bovine
serum, and were maintained in an incubator at 37 °C in
5 % CO2.
5-FU and IFN gamma treatment
On the day of treatment, cells were trypsinized and
seeded into 6-well plates. The cell volume was calculated
to correspond to 75–85 % confluency in the untreated
wells at time of harvest. Six hours post-plating, cells
were treated with plain media, 5-fluorouracil (5-FU; APP
Pharmaceuticals LLC, Schaumberg, IL) or interferon
gamma (IFN- γ; Gemini Bio, West Sacramento, CA) ac-
cording to the doses in the results section of this paper.
Cells were harvested 24 h after treatment initiation.
Western blot analysis
Twenty-fours hours after treatment initiation, the media
was removed and cells were washed with ice-cold
phosphate-buffered saline (PBS). The cells were trypsi-
nized, collected and washed again with PBS to remove
residual trypsin. The cells were lysed in 25 ul of Cell
Lysis Buffer (BD Biosciences, San Jose, CA) containing
Halt Protease Inhibitor Cocktail (Thermo Scientific,
Rockford, IL). The lysates were centrifuged and the
supernatant was collected and stored at −80 °C. Protein
quantification was done using the Pierce BCA Protein
Assay (Thermo Scientific, Rockfold, IL). Forty micro-
grams of protein per treatment condition was loaded
onto 4–12 % Bis-Tris gradient gels and transferred onto
nitrocellulose membranes (BioRad, Hercules, CA). The
membranes were blocked with 5 % non-fat dry milk in
PBS-Tween (PBS-T, 0.2 % Tween) and incubated
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overnight at 4 °C with mouse monoclonal purified anti-
human B7-H1 antibody (clone 9A11, diluted 1:100 CRC
cells, 1:250 OE33). The 9A11 antibody was a generous
gift from Dr. Gordon Freeman (Dana Farber Cancer In-
stitute, Boston, MA). All dilutions were made with 5 %
non-fat dry milk in PBS-T. After washing with PBS-T,
the membranes were incubated with horseradish perox-
idase (HRP)-conjugated mouse secondary antibody
(1:1000) at room temperature. The membranes were
washed and the bands were visualized using Clarity
Western ECL Substrate (BioRad, Hercules, CA) and
Hyclone Film (Thermo Scientific, Rockford, IL).
Membrane were subsequently stripped and re-probed
for actin (1:1000–1:5000 dilutions, Sigma Aldrich, St.
Louis, MO).
Western blots were quantified using ImageJ software
Version 1.50 g. The quantified data are presented as a
ratio of PD-L1 Band Intensity (as calculated by ImageJ)
divided by Actin Band Intensity.
Flow cytometry
Twenty-fours hours after treatment initiation, the media
was removed and cells washed with ice-cold phosphate
buffered saline (PBS). The cells were trypsinized, col-
lected and washed with PBS to remove residual trypsin.
Cells were incubated with PE-anti human CD274 (B7-
H1, clone MIH1) or isotype control antibodies (BD Bio-
sciences, San Jose, CA) for 30 min at 4 °C. Cells were
then washed with PBS before being fixed in 1 % parafor-
maldehyde. B7-H1 surface expression was read using a
BD Accuri C6 flow cytometer (BD Biosciences, San Jose,
CA). The mean fluoroscent intensity of the isotype con-
trol from each experiment was subtracted from the re-
spective samples before plotting the data. If treated
samples had lower values than the isotype control they
were recorded as zero.
PD-L1 expression in patient derived samples
Ten matched pre-neoadjuvant (cisplatin, 5-FU and radi-
ation) and post-esophagectomy samples were provided
by KSN, JMD and JDL. Samples were paraffin-
embedded, cut and stained for B7-H1 using immunohis-
tochemistry according to published procedures [21].
Samples were scored in a blinded fashion by LVDK and
images captured using the EVOS FL Auto Microscope
(Life Technologies, Waltham, MA). Samples were con-
sidered positive if 1 % of the tumor cells showed staining
for B7-H1.
Statistics
All data are presented as mean +/− the standard error of
the mean unless otherwise noted. Continuous variables
were compared between experimental arms using Stu-
dent’s t-test or ANOVA. Results were considered
statistically significant if p < 0.05. When results from
multiple independent experiments are combined, mixed
effects ANOVA is used to account for between-
experiment variation. If an ANOVA is considered statis-
tically significant, the p-values of post-hoc pairwise com-
parisons were adjusted using Westfall's method [22].
Statistical analyses were performed using GraphPad
Prism and R.
Results
5-FU induces B7-H1 surface expression in colorectal can-
cer cell lines
We examined B7-H1 expression in HCT 116 p53+/+ and
HCT 116 p53 −/− cells following 24-h treatment with 5-
FU (0.5 uM, 5 uM, 50 uM, 500 uM) by Western blot
analysis (Fig. 1 a and b). Interferon (IFN)-ɣ is a TH1
cytokine produced and secreted by natural killer and T
cells within the tumor microenvironment. IFN-ɣ can in-
duce B7-H1 expression in several histologic types of tu-
mors and in tumor cells in culture and therefore we
utilized treatment with 10 ng/ul of IFN-ɣ as a positive
control for B7-H1 induction [23, 24]. B7-H1 expression
was barely detectable at baseline with IFN-ɣ eliciting the
highest B7-H1 protein expression (p < 0.001 to un-
treated). Overall levels of B7-H1 induction were low, as
Western analysis required at least 20 min to induce
detectable protein expression. Treatment with doses of 5
uM or higher 5-FU induced B7-H1 expression (p < 0.001)
under our experimental conditions in both HCT 116
p53+/+ and HCT 116 p53 −/− cell lines. While the
HCT 116 p53+/+ cells had higher average B7-H1 ex-
pression (p = 0.013) than the HCT 116 p53−/− cells,
there was no significant interaction between treatment
and p53 status, indicative of a similar trend in induc-
tion within both cell lines. This B7-H1 increase fol-
lowing 5-FU was confirmed at the 50 uM and 500 uM 5-
FU doses (p < 0.02) for both cells lines and for IFN- ɣ in
the HCT 116 p53−/− cells using flow cytometry (Fig. 2).
Colon cancer cells exhibit limited B7-H1 surface expres-
sion at baseline
To determine if low baseline B7-H1 expression was indi-
cative of other CRC cell lines we analyzed B7-H1 surface
expression in HCT116 p53+/+, HCT116 p53 −/−, SW480
and HT29 cells using flow cytometry (Fig. 3). The B7-
H1 histograms remained superimposed on the isotype
control staining and there were non-significant differ-
ences in mean fluorescent intensity (MFI) between the
isotype control and B7-H1 samples suggestive of non-
detectable B7-H1 expression in untreated CRC cells.
Western analysis did not show detectable bands in these
CRC cell lines (data not shown).
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5-FU induces B7-H1 surface expression in OE33 Barrett’s
adenocarcinoma cells
To assess if B7-H1 expression was important in other
gastrointestinal cancers, we examined expression of B7-
H1 in esophageal adenocarcinoma OE33 cells. These
cells are derived from a patient with Barrett’s adenocar-
cinoma, which is associated with intestinal metaplasia
and aggressive malignancy. OE33 cells had higher base-
line expression (untreated) relative to HCT 116 p53 +/+
and HCT 116 p53 −/− cells. We showed by both Western
Blot (Fig. 4) and flow cytometry (Fig. 2) that treatment
with 5-FU (5 uM or higher) and IFN- ɣ induces B7-H1
expression in OE33 cells. It is important to note that
Fig. 1 5-FU treatment promotes B7-H1 protein expression in whole
cell lysates from HCT 116 WT +/+ and HCT 116 p53 −/− colon cancer
cell lines. a Western blots from seven independent experiments
measuring B7-H1 and actin expression in HCT 116 p53+/+ and HCT
116 p53−/− cells. The “X” in experiment # 2 indicates a skipped lane
when loading the samples. Unt = untreated control, 0.5, 5, 50 and
500 = 5FU doses in uM, IFN = 10 ng/ul of interferon gamma.
b Quantification of B7-H1 expression using ImageJ. Data is repre-
sented as mean B7-H1 band intensity/mean actin band intensity +/−
SEM. *** p < 0.001 relative to the untreated control
Fig. 2 5-FU treatment promotes B7-H1 protein surface expression in
HCT 116 p53+/+, HCT 116 p53 −/− and OE33 cells as measured using flow
cytometery. Surface expression of B7-H1 expressed as mean fluorescent
intensity as measured using flow. The isotype control was subtracted
from each individual experiment and values measuring less than the
isotype were assigned an absolute value of zero. Each line represents a
single experiment. * p< 0.02 relative to the untreated control for that
cell line
Fig. 3 Colorectal cancer cell lines express low surface B7-H1 at baseline.
a Representative histograms and b quantification of mean fluorescent
intensity (MFI) for baseline B7-H1 surface expression compared to the
isotype control in HCT116 p53+/+, HCT116 p53−/−, SW480 and HT29
colorectal cancer cell lines (n= 3). The SW480 cells carry R273H and
P309S homozygous mutations at p53 and the HT29 have a homozygous
R273H mutation
Van Der Kraak et al. Journal for ImmunoTherapy of Cancer  (2016) 4:65 Page 4 of 8
with similar exposure times no evidence of B7-H1 was
seen in the CRC treated cells, indicative of higher overall
expression in the OE33 cells. B7-H1 expression was dose
dependent in our Western analysis, with evidence of two
distinct bands, with the lower band rarely seen in the
CRC cell lines (Fig. 1 a). The lower band may reference
a second PD-L1 isoform identified by He et al., but add-
itional analysis is necessary [25]. Overall, the OE33 cells
had a significant induction of B7-H1 following 5-FU
treatment that was significantly higher than our CRC
cell lines.
B7-H1 protein is detectable by immunohistochemistry in
esophageal adenocarcinoma biopsies
We have shown that B7-H1 expression can be induced
in a 5-FU dose dependent manner in OE33 cells. To de-
termine if a similar increase could be observed in
esophageal adenocarcinoma patients treated with 5-FU
containing regimes we compared PD-L1 expression in
10 matched pre- and post-treatment (5-FU, cisplatin and
radiation therapy) tissue samples using immunohisto-
chemistry. All samples showed positive scoring for B7-
H1 expression on immune cells (CD68+ macrophages,
CD3+ T-cells), with no obvious correlations with respect
to extent of infiltrate between the pre and post treat-
ment specimens (Figs. 5 c and d). We observed positive
B7-H1 scoring in 40 % of the pre-treatment biopsies
(Fig. 5 a–c). Contrary to our in vitro studies, enhanced
B7-H1 expression was not observed on tumor cells in
the post-treatment samples (Fig. 5 a). This may be due
to the staining antibody employed and the noted diffi-
culties in immune-histochemical consistent identifica-
tion of this moiety.
Discussion
B7-H1 is a negative co-stimulatory molecule that is
expressed in many cancers, whose expression plays a
pivotal role in the ability of tumor cells to evade the host
response [11]. Since a few studies have also demon-
strated increased B7-H1 expression following treatment
with chemotherapeutic agents (since submission of this
manuscript), we investigated if 5-FU could have a similar
effect in gastrointestinal cancers [13–15]. We treated
HCT 116 p53+/+ and HCT 116 p53−/− CRC cells lines
and OE33 Barrett’s carcinoma cells with 5-FU and stud-
ied B7-H1 expression using flow cytometry and western
blot analysis.
Consistent with previous studies, we have shown that
IFN-γ can induce B7-H1 protein expression [23, 24]. We
also demonstrate that treatment with 5 uM or higher 5-
FU can induce B7-H1 upregulation in HCT 116 cells as
detected by western blot analysis, regardless of p53 mu-
tational status. B7-H1 surface expression, detected by
flow cytometry, was observed in HCT cells treated with
50–500 uM 5-FU. Differences between western and flow
analysis may reflect differences in surface vs intracellular
expression or may be influenced by dead or dying cells,
which can be excluded from analysis using flow. HCT
116 cells have functional MSH2, but non-functional
MSH1 and are therefore classified as a microsatellite in-
stable cell line (MSI) [26, 27]. MSI tumors have been
shown to upregulate multiple immune checkpoints in-
cluding PD-1 and B7-H1, with microsatellite stable tu-
mors being less responsive and therefore our HCT 116
cells could be expected to be ideal for studying B7-H1
induction [28, 29]. Recently, a phase II trial demon-
strated clinical benefit of immune checkpoint blockade
with an anti-PD-1 antibody (pembrolizumab) in MSI-hi
CRC patients [30]. We demonstrate that baseline B7-H1
is low in SW480 and HT29 CRC cells, consistent with
other studies demonstrating low B7-H1 expression on tu-
mors at baseline [11]. Combining 5-FU-based therapy with
anti PD-1/B7-H1 pathway inhibitors might be a potential
strategy to overcome 5-FU-induced immunoresistance, and
Fig. 4 5-FU treatment promotes B7-H1 protein expression in a dose
dependent manner in OE33 esophageal adenocarcinoma cells.
a Western blots from three independent experiments measuring B7-H1
and actin expression. Unt = untreated control, 0.5, 5, 50 and 500 = doses
in uM of 5FU, IFN = 10 ng/ul of interferon gamma. b Quantification of
B7-H1 expression using ImageJ. Data is represented as mean PD-L1 band
intensity/mean actin band intensity +/− SEM. *** p< 0.001 relative to the
untreated control
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thereby improve the clinical outcomes of CRC patients.
Further preclinical and clinical studies are warranted to for-
mally test this hypothesis and determine if the 5-FU levels
of induction correspond to therapeutically targetable levels.
B7-H1 expression was also induced in a dose
dependent manner in OE33 EAC cells and to a signifi-
cantly higher extent than the HCT 116 cells. Interest-
ingly, we saw more than one band for B7-H1 in our
OE33 cell western blot analysis. Additional testing is ne-
cessary to determine if these bands correspond to differ-
ent B7-H1 isoforms or variations in the glycosylation
pattern of the B7-H1 protein [25, 31, 32].
To test for 5-FU upregulation following neoadjuvant
treatment in EAC patient samples we obtained matched
pre-neoadjuvant (cisplatin, 5-FU, radiation) and post-
neoadjuvant samples from 10 EAC patients. We detected
positive B7-H1 staining in 40 % of pre-treatment patient
samples, which was slightly higher than observed previously
[12, 21]. However, this was significantly lower than Loos et
al., who showed 73 % B7-H1 staining in Barrett’s-associated
EAC, which has higher B7-H1 expression than non-
Barrett’s EAC [20]. We did not detect any B7-H1 staining
in our post-treatment samples. There are several possible
explanations for these observations 1) B7-H1 tumor expres-
sion is heterogeneous and it is not known if our biopsy
and esophagectomy samples correspond to identical tu-
mors/regions of tumor [31]. 2) B7-H1 expression has also
been demonstrated to occur primarily along the invasive
front of the tumor and many post-treatment samples
lacked a clearly defined regions of tumor [33]. 3) It is also
not clear if B7-H1 expression is upregulated following re-
moval of the initial 5-FU stimuli in our cell lines. Therefore,
it is plausible that B7-H1 expression is transient in patients
undergoing neoadjuvant therapy and therefore obtaining
esophageal biopsies mid-treatment may better reflect the
conditions necessary to detect B7-H1 upregulation in EAC
patients. 4) B7-H1 expression is associated more strongly
with Barrett’s associated EAC and the Barrett’s status
of our samples is unknown. Testing of additional
EAC samples from patients with advanced metastatic
disease will be necessary and hopefully will demon-
strate similar results to a recent study that showed
increased B7-H1 expression following chemotherapy
and radiation therapy for esophageal squamous cell
carcinoma [34]. We also wish to the assess expression
of the second PD-1 ligand, B7-DC, in these same
cells and samples. Derks et al. have shown high levels
of B7-DC in OE33 and EAC patient samples at base-
line, however it is not known if chemotherapy can
also alter B7-DC expression [21].
Fig. 5 B7-H1 is not upregulated following treatment with neoadjuvant therapy in esophageal adenocarcinoma tissue samples. a Percent positivity of
patient samples comparing pre-neoadjuvant (cisplatin, 5-FU and radiation) therapy biospies to matched post-neoadjuvant esophagectomys (cisplatin, 5-FU
and radiation). b and c B7-H1 expression in two representative pre-treatment specimens using immunohistochemistry (40 ×). d and e Representative
images showing B7-H1 expression on immune cells, but not on tumor cells (40 ×)
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Conclusions
B7-H1 overexpression is an important mechanism by
which tumor cells can escape host-T cell immunity. We
have demonstrated that while B7-H1 expression is low
at baseline its expression can be induced in HCT 116
p53+/+, HCT 116 p53−/− and OE33 cells following treat-
ment with 5-FU, the chemotherapy of choice for both
advanced CRC and EAC. We hypothesize that this in-
crease in B7-H1 following chemotherapeutic treatment
may contribute in part to the chemoresistance that de-
velops following 5-FU treatment. While we did not find
a corresponding increase in post-neoadjuvant treated
esophageal adenocarcinoma tissue samples, we recognize
that we had a limited number of samples and that 5-FU
induced B7-H1 could be transient since the underlying
mechanisms of B7-H1 upregulation remains unknown.
We postulate that counteracting the immunosuppressive
cofactor B7-H1 using PD-1/B7-H1 blockade might en-
hance the anti-cancer effects of 5-FU in the management
of gastrointestinal cancers. Future experiments will
therefore, involve co-culture of 5-FU treated colon can-
cer cells with PD-1+/CD8+ T-cells to evaluate T-cell
apoptosis and will examine if anti-PD-1/B7-H1 blockade
inhibits this process. This would further help establish
any potential synergism between 5-FU-based chemo-
therapy and PD-1/B7-H1 blockade in the management
of patients with gastrointestinal cancers.
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